Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?

uniQure (QURE) shares surged 247.7% to $47.5 after announcing positive Phase I/II study results for its investigational gene therapy, AMT-130, in Huntington’s disease. The high-dose treatment significantly slowed disease progression by 75% on cUHDRS and 60% on TFC at 36 months, demonstrating potential as a disease-modifying therapy, with a regulatory filing planned for early 2026. Despite anticipated strong revenue growth, the unchanged consensus EPS estimate for the upcoming quarter suggests that sustained upward momentum may hinge on future earnings estimate revisions.

Analysis

uniQure (QURE) experienced a 247.7% share price rally to $47.50 on significant trading volume, a direct result of positive data from its pivotal Phase I/II study for AMT-130, an investigational gene therapy for Huntington’s disease. The catalyst was the achievement of primary and key secondary endpoints, with the high-dose treatment demonstrating a 75% reduction in disease progression on the cUHDRS scale and a 60% reduction on the TFC scale at the 36-month mark against a matched control. This robust clinical data positions AMT-130 as a potential disease-modifying therapy and has set a clear forward catalyst with a planned regulatory filing in early 2026. While the company's upcoming quarterly revenue is projected to grow 202.8% to $6.93 million, a key counterpoint is that the consensus EPS estimate has remained unchanged over the last 30 days. This stagnation in earnings estimates may present a headwind, as sustained stock price increases typically require corresponding upward revisions from analysts.

Key Decisions for Investors

• The positive AMT-130 data represents a significant de-risking event and a major valuation inflection point, potentially justifying a long-term bullish position for investors with a high-risk tolerance focused on the 2026 regulatory filing catalyst.
• Given the magnitude of the 247.7% single-day rally, investors should be prepared for significant short-term volatility and the possibility of profit-taking.
• Monitor analyst earnings estimate revisions closely in the coming weeks, as positive revisions will be critical to validate the new valuation and support further price appreciation beyond the initial clinical data reaction.